Only NGS-based panel for CLL that offers information for patient risk stratification, disease management, and treatment selection
Focus::CLL addresses a significant market of over 120,000 patients in the US living with CLL, the most common form of leukemia in the Western hemisphere
Focus::CLL is available for both routine patient diagnosis and management as well as clinical trials for CLL
RUTHERFORD, N.J., Dec.
for Cancer Genetics, Inc. Announces Launch of Targeted Next Generation Sequencing Based Panel for Chronic Lymphocytic Leukemia, Focus::CLL investment picks